<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680018</article-id><article-id pub-id-type="doi">10.3390/ph17121582</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-17-01582</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Study of Cytotoxicity of Spiro-Fused [3-Azabicyclo[3.1.0]hexane]oxindoles and Cyclopropa[a]pyrrolizidine-oxindoles Against Tumor Cell Lines <xref rid="fn1-pharmaceuticals-17-01582" ref-type="author-notes">&#x02020;</xref></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kornev</surname><given-names>Anton A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-pharmaceuticals-17-01582" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Shmakov</surname><given-names>Stanislav V.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-pharmaceuticals-17-01582" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ponyaev</surname><given-names>Alexander I.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af2-pharmaceuticals-17-01582" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Stepakov</surname><given-names>Alexander V.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af2-pharmaceuticals-17-01582" ref-type="aff">2</xref><xref rid="af3-pharmaceuticals-17-01582" ref-type="aff">3</xref><xref rid="c1-pharmaceuticals-17-01582" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4857-2046</contrib-id><name><surname>Boitsov</surname><given-names>Vitali M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-pharmaceuticals-17-01582" ref-type="aff">1</xref><xref rid="c1-pharmaceuticals-17-01582" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>De Sousa</surname><given-names>Maria Em&#x000ed;lia</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Berzal-Herranz</surname><given-names>Alfredo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-17-01582"><label>1</label>Laboratory of Nanobiotechnologies, Saint-Petersburg National Research Academic University of the Russian Academy of Sciences, Saint Petersburg 194021, Russia</aff><aff id="af2-pharmaceuticals-17-01582"><label>2</label>Saint-Petersburg State Institute of Technology, Saint Petersburg 190013, Russia</aff><aff id="af3-pharmaceuticals-17-01582"><label>3</label>Department of Chemistry, Saint-Petersburg State University, Saint Petersburg 199034, Russia</aff><author-notes><corresp id="c1-pharmaceuticals-17-01582"><label>*</label>Correspondence: <email>alstepakov@yandex.ru</email> (A.V.S.); <email>bovitali@yandex.ru</email> (V.M.B.)</corresp><fn id="fn1-pharmaceuticals-17-01582"><label>&#x02020;</label><p>This article is a revised and expanded version of a paper entitled &#x0201c;Study of cytotoxicity of spiro-fused [3-azabicyclo[3.1.0]hexane]oxindoles against tumor cell lines&#x0201d;, which was presented at 8th International Electronic Conference on Medicinal Chemistry, Basel, Switzerland, 1&#x02013;30 November 2022.</p></fn></author-notes><pub-date pub-type="epub"><day>25</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>17</volume><issue>12</issue><elocation-id>1582</elocation-id><history><date date-type="received"><day>24</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>18</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: A series of spiro-fused heterocyclic compounds containing cyclopropa[a]pyrrolizidine-2,3&#x02032;-oxindole and 3-spiro[3-azabicyclo[3.1.0]-hexane]oxindole frameworks were synthesized and studied for their in vitro antiproliferative activity against human erythroleukemia (K562), cervical carcinoma (HeLa), acute T cell leukemia (Jurkat), melanoma (Sk-mel-2) and breast cancer (MCF-7) as well as mouse colon carcinoma (CT26) cell lines. <bold>Methods</bold>: Cell proliferation was evaluated in vitro by MTS assay. Confocal microscopy was used to study actin cytoskeleton structure and cell motility. Cell cycle analysis was evaluated by flow cytometry. <bold>Results</bold>: It was found that compounds <bold>4</bold>, <bold>8</bold>, <bold>18</bold> and <bold>24</bold> showed antiproliferative activity against the Jurkat, K-562, HeLa and Sk-mel-2 cell lines with IC<sub>50</sub> ranging from 2 to 10 &#x003bc;M (72 h). Evaluation of the impact on cell cycle progression showed that the tested compounds achieved significant cell-cycle perturbation with a higher accumulation of cells in the SubG1 and G0/G1 phases of the cell cycle, in comparison to the negative control. I Incubation with tested compounds led to the disappearance of stress fibers (granular actin was distributed diffusely in the cytoplasm in up to 38% of treated HeLa cells) and changes in the number of filopodia-like deformations (reduced from 93% in control cells to 64% after treatment). The impact on the Sk-mel-2 cell actin cytoskeleton structure was even greater: granular actin was distributed diffusely in the cytoplasm in up to 90% of treated cells while the number of filopodia-like deformations was reduced by up to 23%. A scratch test performed on the human melanoma cell line showed that these cells did not fill the scratched strip and lose their ability to move under treatment. <bold>Conclusions</bold>: The obtained results support the antitumor effect of the tested spiro-compounds and encourage the extension of this study in order to improve their anticancer activity as well as reduce their toxicological risks.</p></abstract><kwd-group><kwd>3-spiro[3-azabicyclo[3.1.0]-hexane]oxindole</kwd><kwd>cyclopropa[a]pyrrolizidine-2,3&#x02032;-oxindole</kwd><kwd>antiproliferative activity</kwd><kwd>cell cycle</kwd><kwd>morphological changes (cytoskeleton)</kwd><kwd>cell motility</kwd><kwd>tumor cell lines</kwd><kwd>1,3-dipolar cycloaddition</kwd><kwd>azomethine ylides</kwd><kwd>cyclopropenes</kwd></kwd-group><funding-group><award-group><funding-source>Ministry of Education and Science of the Russian Federation</funding-source><award-id>FSRM-2023-0005</award-id><award-id>FSEN-2023-0002</award-id></award-group><funding-statement>This research was financially supported by the Ministry of Education and Science of the Russian Federation (Projects FSRM-2023-0005 and FSEN-2023-0002).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-17-01582"><title>1. Introduction</title><p>Oncological diseases are one of the most common and lethal diseases in the world and, after cardiovascular diseases, they are the second leading cause of death. The rise of drug resistance and emergence of tumor resistance, along with significant side effects from chemotherapy, diminish the effectiveness of existing anticancer medications and treatments. Although targeted therapies and immunotherapy have shown promising results in specific patients, finding new medications that can help is still a big challenge. Additionally, the emergence of tumor resistance necessitates the creation of anticancer drugs that are not merely variations of traditional drugs but are derived from entirely new compounds. Following these achievements and improvements in cancer understanding, tumor treatment modalities have undergone a remarkable transformation as well [<xref rid="B1-pharmaceuticals-17-01582" ref-type="bibr">1</xref>].</p><p>Isolated from microorganisms, natural plant and animal products are prominent sources for anticancer drug research and development [<xref rid="B2-pharmaceuticals-17-01582" ref-type="bibr">2</xref>]. Their enormous number and tremendous structural diversity make them a gift from nature for lead-molecule discoveries. Therefore, natural products and synthetic compounds inspired by them remain outstanding sources for new drug candidates. Many of the anticancer drugs currently in use or undergoing clinical trials are either derived from natural sources or designed based on naturally occurring substances. Most often, these substances are compounds of complex structure that can be produced as a result of multistage synthesis only. Recent progress in complex hetero-system synthesis has sparked considerable interest in creating effective methods for producing various derivatives and structural analogues of these compounds.</p><p>Cycloaddition reactions play a pivotal role in organic synthesis by facilitating the formation of cyclic compounds with desirable properties. Among them, 1,3-dipolar cycloaddition reactions have long been recognized as being important for the synthesis of heterocyclic rings. Using new stable or in situ-generated building blocks allows their further modification and diversification. Azomethine ylides are remarkably versatile building blocks in organic synthesis and are known to take part in 1,3-dipolar cycloaddition reactions with a wide range of dipolarophiles. Cycloadditions of azomethine ylides to alkenes and cycloalkenes are well-established reactions in which a wide variety of (poly)hetecyclic scaffolds are formed (including azabicyclo[3.1.0]hexane and azabicyclo[3.3.0]octane scaffolds) [<xref rid="B3-pharmaceuticals-17-01582" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-17-01582" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceuticals-17-01582" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceuticals-17-01582" ref-type="bibr">6</xref>].</p><p>Pyrrolizines and pyrrolizidine alkaloids (both containing a 1-azabicyclo[3.3.0]octane core) as well as their analogues are challenging synthetic targets that are of interest to many medicinal chemists [<xref rid="B7-pharmaceuticals-17-01582" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-17-01582" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceuticals-17-01582" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-17-01582" ref-type="bibr">10</xref>] because of their unique structural features and their biological and pharmacological activities (such as antimicrobial [<xref rid="B11-pharmaceuticals-17-01582" ref-type="bibr">11</xref>], antitumor [<xref rid="B12-pharmaceuticals-17-01582" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceuticals-17-01582" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceuticals-17-01582" ref-type="bibr">14</xref>], anti-inflammatory [<xref rid="B15-pharmaceuticals-17-01582" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceuticals-17-01582" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceuticals-17-01582" ref-type="bibr">17</xref>] and anticoagulant (serine protease thrombin inhibitor) effects [<xref rid="B18-pharmaceuticals-17-01582" ref-type="bibr">18</xref>]).</p><p>The azabicyclo[3.1.0]hexane moiety is another important scaffold found in many natural products [<xref rid="B19-pharmaceuticals-17-01582" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceuticals-17-01582" ref-type="bibr">20</xref>]; these are used in pharmaceuticals [<xref rid="B21-pharmaceuticals-17-01582" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-17-01582" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceuticals-17-01582" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceuticals-17-01582" ref-type="bibr">24</xref>] or as valuable intermediate products [<xref rid="B25-pharmaceuticals-17-01582" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceuticals-17-01582" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceuticals-17-01582" ref-type="bibr">27</xref>]. Compounds with azabicyclo[3.1.0]hexane scaffolds show anti-inflammatory [<xref rid="B16-pharmaceuticals-17-01582" ref-type="bibr">16</xref>], antitumor [<xref rid="B28-pharmaceuticals-17-01582" ref-type="bibr">28</xref>], anti-neurodegenerative [<xref rid="B29-pharmaceuticals-17-01582" ref-type="bibr">29</xref>] and antibacterial activity [<xref rid="B30-pharmaceuticals-17-01582" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-17-01582" ref-type="bibr">31</xref>]; they are antagonists of opioid receptors [<xref rid="B23-pharmaceuticals-17-01582" ref-type="bibr">23</xref>,<xref rid="B26-pharmaceuticals-17-01582" ref-type="bibr">26</xref>] and dopamine D3 receptors [<xref rid="B32-pharmaceuticals-17-01582" ref-type="bibr">32</xref>].</p><p>The spiro[pyrrolidine-3,3&#x02032;-oxindole] moiety is an important scaffold found in a many natural products, pharmaceuticals and biologically active compounds and therefore has served as an inspiration for the development of new therapeutics. This structural fragment is present in oxindole alkaloids characterized by a spiro-fusion of an indole core to a pyrrolidine ring. Such oxindole alkaloids possess a variety of pharmacological properties (cardiovascular [<xref rid="B33-pharmaceuticals-17-01582" ref-type="bibr">33</xref>], neuroprotective [<xref rid="B34-pharmaceuticals-17-01582" ref-type="bibr">34</xref>], antiviral [<xref rid="B35-pharmaceuticals-17-01582" ref-type="bibr">35</xref>] and anticancer [<xref rid="B36-pharmaceuticals-17-01582" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceuticals-17-01582" ref-type="bibr">37</xref>]).</p><p>Selected examples of biologically active 1-azabicyclo[3.3.0]octanes (pyrrolizines or pyrrolizidines), 3-azabicyclo[3.1.0]hexanes and spiro[pyrrolidine-3,3&#x02032;-oxindoles] are presented in <xref rid="pharmaceuticals-17-01582-f001" ref-type="fig">Figure 1</xref>.</p><p>In previous studies by our research group, differently substituted cyclopropenes were widely used as dipolarophiles in 1,3-dipolar cycloaddition reactions generated from the corresponding ketones and <italic toggle="yes">&#x003b1;</italic>-amino acids azomethine ylides. Derivatives of alloxan [<xref rid="B38-pharmaceuticals-17-01582" ref-type="bibr">38</xref>], isatin [<xref rid="B39-pharmaceuticals-17-01582" ref-type="bibr">39</xref>], tryptanthrin [<xref rid="B40-pharmaceuticals-17-01582" ref-type="bibr">40</xref>], ninhydrin [<xref rid="B41-pharmaceuticals-17-01582" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceuticals-17-01582" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-17-01582" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceuticals-17-01582" ref-type="bibr">44</xref>] and 11<italic toggle="yes">H</italic>-indeno[1,2-<italic toggle="yes">b</italic>]quinoxalin-11-one [<xref rid="B45-pharmaceuticals-17-01582" ref-type="bibr">45</xref>] were used as the ketone components. The products of these reactions were pharmacologically interesting spiro-fused 1-azabicyclo[3.3.0]octanes and 3-azabicyclo[3.1.0]hexanes, some of which were identified as exhibiting in vitro antiproliferative activity [<xref rid="B46-pharmaceuticals-17-01582" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceuticals-17-01582" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceuticals-17-01582" ref-type="bibr">48</xref>].</p><p>We here report a study of spiro-fused [3-azabicyclo[3.1.0]hexane]oxindoles and cyclopropa[a]pyrrolizidine-2,3&#x02032;-oxindoles (readily available via one-pot three-component 1,3-dipolar cycloadditions of various cyclopropenes with azomethine ylides generated in situ from isatins) for their antiproliferative activity against selected tumor cell lines as well as their morphological changes, cell motility and cell cycle perturbations under treatment with the most active products. This article is a revised and expanded version of a paper entitled &#x0201c;Study of cytotoxicity of spiro-fused [3-azabicyclo[3.1.0]hexane]oxindoles against tumor cell lines&#x0201d;, which was presented at 8th International Electronic Conference on Medicinal Chemistry, 1&#x02013;30 November 2022, MDPI: Basel, Switzerland [<xref rid="B48-pharmaceuticals-17-01582" ref-type="bibr">48</xref>].</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-17-01582"><title>2. Results and Discussion</title><sec id="sec2dot1-pharmaceuticals-17-01582"><title>2.1. Chemistry</title><p>Desired spiroadducts were synthesized via three-component one-pot 1,3-dipolar cycloaddition reactions of accordingly substituted cyclopropenes with generated in situ isatin-derived azomethine ylides either as a single (major) isomer or as a mixture of two diastereomeres with up to 85% overall isolation yield (<xref rid="pharmaceuticals-17-01582-t001" ref-type="table">Table 1</xref>). The <italic toggle="yes">major</italic> to <italic toggle="yes">minor</italic> ratio in diastereomeric mixtures was found to be within a range of &#x0003e;20&#x02013;2 to 1, correspondingly. Structures of both diastereomers were assigned on the basis of NMR spectra analysis and unequivocally verified by X-ray crystal analysis (synthesis and structure elucidation was described in detail by us earlier [<xref rid="B39-pharmaceuticals-17-01582" ref-type="bibr">39</xref>,<xref rid="B49-pharmaceuticals-17-01582" ref-type="bibr">49</xref>]).</p><p>Despite not all cycloadducts being isolated as single diastereomers and some of them being obtained as an inseparable mixture of two diastereomers, it was decided to study all of them for their in vitro antiproliferative activity against human cancer cell lines. Taking into account that diastereomers may have different activity profiles, mixtures with low activity will not need any further separation trials, while additional steps will be required for those exhibiting considerable activity.</p><p>To preliminarily determine whether the synthesized spiro-fused [3-azabicyclo[3.1.0]hexane]oxindoles and cyclopropa[a]pyrrolizidine-2,3&#x02032;-oxindoles have drug-like properties, an in silico analysis was performed to determine their physicochemical profile using the free online software SwissADME (<uri xlink:href="http://www.swissadme.ch/">http://www.swissadme.ch/</uri>, accessed on 12 November 2024).</p><p>The molecular descriptors were calculated according to Lipinski&#x02019;s rule of five. According to the rule, orally active drugs should not violate more than one of the following criteria: molecular weight MW &#x0003c; 500 Da, number of hydrogen bond donor HBD &#x0003c; 5, number of hydrogen bond acceptor HBA &#x0003c; 10, number of rotatable bonds nRotB &#x0003c; 10, octanol/water partition coefficient Log P &#x0003c; 5, and topological polar surface area TPSA &#x0003c; 140 &#x000c5;<sup>2</sup>. The obtained results are presented in <xref rid="pharmaceuticals-17-01582-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec2dot2-pharmaceuticals-17-01582"><title>2.2. Biology</title><p>Cancer cell lines are valuable in vitro model systems that are widely used in cancer research and drug discovery. Their use is mainly linked to their possibility to provide for experimental purposes an unlimited source of biological material. Here, the 24 and 72 h in vitro MTS assay was used to determine the antiproliferative activity of synthesized spiro-fused cyclopropa[a]pyrrolizidine-2,3&#x02032;-oxindoles and [3-azabicyclo[3.1.0]hexane]-oxindoles against human erythroleukemia (K562), acute T cell leukemia (Jurkat), cervical carcinoma (HeLa), melanoma (Sk-mel-2), breast cancer adenocarcinoma (MCF-7) as well as mouse colon carcinoma (CT26) cell lines. It was found that synthesized spiro-fused derivatives significantly reduced the cell proliferation in a time- and concentration-dependent manner. The data for most active compounds are presented in <xref rid="pharmaceuticals-17-01582-f002" ref-type="fig">Figure 2</xref>, <xref rid="pharmaceuticals-17-01582-f003" ref-type="fig">Figure 3</xref>, <xref rid="pharmaceuticals-17-01582-f004" ref-type="fig">Figure 4</xref>, <xref rid="pharmaceuticals-17-01582-f005" ref-type="fig">Figure 5</xref>, <xref rid="pharmaceuticals-17-01582-f006" ref-type="fig">Figure 6</xref> and <xref rid="pharmaceuticals-17-01582-f007" ref-type="fig">Figure 7</xref>. The full results of these investigations are presented in the <xref rid="app1-pharmaceuticals-17-01582" ref-type="app">Supporting Information Figures S1&#x02013;S6</xref>. Half maximal inhibitory concentration (IC<sub>50</sub>) values of most active spiro-fused adducts against tested cell lines for 24 and 72 h are presented in <xref rid="pharmaceuticals-17-01582-t003" ref-type="table">Table 3</xref>. All the tested compounds did not show acute toxicity during the cell proliferation study. An evaluation of the cytotoxicity of the selected compounds towards normal cells (peripheral blood mononuclear cells) was performed additionally to understand their respective relative selectivities. The selectivity index was obtained using the ratio of measured cytotoxicity between the PBMC cells and each of the cancer cell lines, and the results are presented in <xref rid="pharmaceuticals-17-01582-t003" ref-type="table">Table 3</xref>.</p><p>It is obvious from the obtained data that [3-azabicyclo[3.1.0]hexane]-oxindole derivatives usually show better antiproliferative activity as compared to cyclopropa[a]pyrrolizidine-2,3&#x02032;-oxindole derivatives. Indeed, among the latter, only adduct <bold>2</bold> exhibited significant antiproliferative activity with IC<sub>50</sub> ranging from 2 &#x000b1; 0.2 to 12 &#x000b1; 2 &#x003bc;g/mL (except for the breast cancer cell line), that equals to 4&#x02013;23 &#x003bc;M.</p><p>The acute T cell leukemia cell line (Jurkat) was the most sensitive to the screened compounds among the tested cancer cell lines with IC<sub>50</sub> ranging from 1 &#x000b1; 0.2 to 6 &#x000b1; 1 &#x003bc;g/mL (72 h), that equals to 4&#x02013;12 &#x003bc;M.</p><p>It was noticed that products with an unsubstituted nitrogen atom in the oxindol unit were more active against all studied cell lines. Indeed, adducts bearing methyl, phenyl or benzyl substituents fitted to oxindole nitrogen exhibited less activity. At the same time, among the tested products, those bearing three phenyl substituents at the cyclopropane unit were usually more effective. All the active compounds significantly reduced proliferative activity at concentrations less than 10 &#x003bc;g/mL. Since cycloadducts <bold>2</bold>, <bold>4</bold>, <bold>22</bold> and <bold>23</bold> consist of diastereomer mixtures at a range of 5&#x02013;2 to 1, additional attempts are required for their separation and isolation as single isomers. If it is assumed that other isomers exhibit no activity, this can lead to a 2&#x02013;5-fold activity increase.</p><p>Based on the obtained data, compounds that showed better antiproliferative activity were selected for further evaluation of their impact on cell motility, cytoskeletal morphology and progression of the cell cycle.</p></sec><sec id="sec2dot3-pharmaceuticals-17-01582"><title>2.3. Actin Cytoskeleton Changes</title><p>It is known that actin plays an important role in vital cellular processes, providing a number of functions such as cell adhesion, migration and morphogenesis [<xref rid="B50-pharmaceuticals-17-01582" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceuticals-17-01582" ref-type="bibr">51</xref>]. The actin cytoskeleton may serve as an additional target of antitumor chemotherapy [<xref rid="B52-pharmaceuticals-17-01582" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceuticals-17-01582" ref-type="bibr">53</xref>]. Tumor transformation causes reorganization of the actin cytoskeleton, leading to changes in cell motility. A correlation between increased tumor cell migration activity and actin assembly and organization was observed [<xref rid="B54-pharmaceuticals-17-01582" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceuticals-17-01582" ref-type="bibr">55</xref>]. Actin organization structural features can serve as criteria for assessing metastasis potential [<xref rid="B56-pharmaceuticals-17-01582" ref-type="bibr">56</xref>]. The HeLa cell line is extensively used to analyze actin cytoskeleton structure and is characterized by the presence of filopodia and actin stress fibers [<xref rid="B57-pharmaceuticals-17-01582" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceuticals-17-01582" ref-type="bibr">58</xref>].</p><p>The structure of the actin cytoskeleton of HeLa and Sk-mel-2 cells was assessed after the impact of the most active spiro-fused oxindole derivatives by the availability of stress fibers and the presence of filopodia-like protrusions.</p><p>It was found using confocal microscopy that incubation with spiro-fused [3-azabicyclo[3.1.0]hexane]oxindoles <bold>4</bold>, <bold>8</bold>, <bold>17</bold>, <bold>18</bold>, <bold>22</bold>, <bold>24</bold> and cyclopropa[a]pyrrolizidine-2,3&#x02032;-oxindole <bold>2</bold> led to significant changes in the HeLa cells&#x02019; actin cytoskeleton structure leading to the disappearance of stress fibers (granular actin was distributed diffusely in the cytoplasm in up to 38% of treated cells) and changes in the number of filopodia-like deformations (reduced from 93% in control cells to 64% after treatment). The impact on the Sk-mel-2 cells&#x02019; actin cytoskeleton structure was even greater: granular actin was distributed diffusely in the cytoplasm in up to 90% of treated cells while the number of filopodia-like deformations was reduced by up to 23%. Such changes in the cytoskeleton may indicate a change in the motor activity of cells, which may indicate a decrease in the ability of tumor cells to metastasize. At the same time, experimental effects did not cause fragmentation of the nucleus, which indicates the absence of pro-apoptotic activity. Data on actin cytoskeleton structure as well as histograms demonstrating the percentage of cells with filopodia-like deformations and disassembled stress fibers are combined in <xref rid="pharmaceuticals-17-01582-f008" ref-type="fig">Figure 8</xref> and <xref rid="pharmaceuticals-17-01582-f009" ref-type="fig">Figure 9</xref>.</p></sec><sec id="sec2dot4-pharmaceuticals-17-01582"><title>2.4. Inhibition of Cell Motility Evaluated by Scratch Test</title><p>Cell motility is a basic and ancient cellular behavior that is caused by cell invasion and metastasis [<xref rid="B59-pharmaceuticals-17-01582" ref-type="bibr">59</xref>]. Metastasis is one of the main causes of mortality of cancer patients that accounts for about 90% of cancer-related deaths. The process of metastasis is the migration of cancer cells from their originating site to distant organs [<xref rid="B60-pharmaceuticals-17-01582" ref-type="bibr">60</xref>]. A major challenge in understanding metastatic tumor spread in patients is that the process cannot be observed or manipulated directly. The scratch test is a simple model used to assess the impact of different effects on cell motility and metastasis.</p><p>To assess the potential ability of spiro-fused [3-azabicyclo[3.1.0]hexane]oxindoles <bold>4</bold>, <bold>11</bold>, <bold>12</bold>, <bold>18</bold>, <bold>24</bold> and cyclopropa[a]pyrrolizidine-2,3&#x02032;-oxindole <bold>2</bold> to inhibit metastasis associated with cell motility, a scratch test was performed on the human melanoma (Sk-mel-2) cell line. Different fields were analyzed by bright field, and each scratch area was photographed at 0 and 36 h for non-toxic and fast cell visualization. The results are shown in <xref rid="pharmaceuticals-17-01582-f010" ref-type="fig">Figure 10</xref>. Nontreated Sk-mel-2 cells filled 69.5 &#x000b1; 17.2, 41.5 &#x000b1; 5.3, 59.7 &#x000b1; 8.1, 49.3 &#x000b1; 5.3, 43.0 &#x000b1; 12.6, 26.1 &#x000b1; 2.5 and 55.9 &#x000b1; 8.6% of the the scratched strip while under treatment with spiro-fused oxindole derivatives <bold>2</bold>, <bold>4</bold>, <bold>11</bold>, <bold>12</bold>, <bold>18</bold> and <bold>24</bold> cells, respectively. Therefore, treated Sk-mel-2 cells lost their ability to move and did not fill the scratched strip; however their structure&#x02013;activity relationship needs further evaluation. The presented results indicate that the tested compounds can block the cellular movement of tumor cells.</p></sec><sec id="sec2dot5-pharmaceuticals-17-01582"><title>2.5. Cell Cycle Analysis</title><p>Since growth inhibition may be a result of cell cycle arrest at a particular point, the specific antiproliferative activity of several cycloadducts was further evaluated by flow cytometry to study their impact on the progression of the cell cycle in K562 cells. The assay utilizes propidium iodide-based staining of DNA content to distinguish and measure the accumulation of cells in each cell cycle phase (SubG, G0/G1, S and G2/M).</p><p>Analysis of the experimental results showed that screened spiro-fused [3-azabicyclo[3.1.0]hexane]oxindole derivatives <bold>4</bold>, <bold>8</bold>, <bold>17</bold>, <bold>18</bold> and cyclopropa[a]pyrrolizidine-2,3&#x02032;-oxindole <bold>2</bold> stopped the K562 cell cycle in SubG1 and G0/G1 phases, in comparison to the negative control (<xref rid="pharmaceuticals-17-01582-f011" ref-type="fig">Figure 11</xref>, <xref rid="pharmaceuticals-17-01582-t004" ref-type="table">Table 4</xref>). Thus, after 24 h incubation with the tested compounds at 10 &#x003bc;g/mL concentration, the accumulation of cells in the G0/G1 phase of the cycle increased from 40.5% (control sample) to 73.5% for compound <bold>8</bold>. The accumulation of cells in the SubG1 phase of the cycle increased from 4.5% (control sample) to 7.7% after incubation with compound <bold>2</bold>. The total percentage of cells in the SubG1 and G0/G1 phases increased from 45.0% to 74.0&#x02013;77.5% after incubation with compounds <bold>2</bold>, <bold>8</bold>, <bold>17</bold> and <bold>18</bold>. The accumulation of cells in the synthetic phase (S) of the cycle was also lower for treated cells (up to 14.3&#x02013;19.0%) than the control sample (31.9%). The accumulation of cells in the G2/M phase of the cycle decreased from 23.1% for the control sample to 5.9&#x02013;8.8% for those treated with compounds <bold>2</bold>, <bold>8</bold>, <bold>17</bold> and <bold>18</bold>.</p><p>Additionally, the concentration-dependent effects of spiro-fused [3-azabicyclo[3.1.0]hexane]oxindole derivatives <bold>4</bold>, <bold>8</bold>, <bold>17</bold>, <bold>18</bold> and cyclopropa[a]pyrrolizidine-2,3&#x02032;-oxindole <bold>2</bold> on cell cycle phase distribution was evaluated. The results of this investigation are summarized in <xref rid="pharmaceuticals-17-01582-t004" ref-type="table">Table 4</xref> and <xref rid="app1-pharmaceuticals-17-01582" ref-type="app">Figure S7</xref>. Analysis of the experimental results showed that, generally, a 24 h incubation of K562 cells with the screened compounds at concentrations of 5, 10 and 20 &#x003bc;g/mL led to further increased SubG1 and G0/G1 populations and decreased S- and G2/M populations.</p><p>These findings indicate that the tested compounds prevent cancer cells from starting DNA division.</p></sec></sec><sec id="sec3-pharmaceuticals-17-01582"><title>3. Materials and Methods</title><sec id="sec3dot1-pharmaceuticals-17-01582"><title>3.1. Chemistry</title><p><sup>1</sup>H (400 MHz) and <sup>13</sup>C (101 MHz) NMR spectra were recorded with a Bruker Avance 400 spectrometer (Bruker Biospin, Rheinstetten, Germany). Chemical shifts are reported in ppm relative to solvent residual signals (7.26 and 77.17 ppm for <sup>1</sup>H and <sup>13</sup>C in CHCl<sub>3</sub>; 2.50 and 39.52 ppm for <sup>1</sup>H and <sup>13</sup>C in DMSO-<italic toggle="yes">d</italic><sub>5</sub>) as internal standards. Melting points were determined using a Boetius instrument. Cyclopropenes were prepared according to the literature data [<xref rid="B61-pharmaceuticals-17-01582" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceuticals-17-01582" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceuticals-17-01582" ref-type="bibr">63</xref>], while &#x003b1;-amino acids and isatins were obtained from commercial sources. Reaction course, purity and individuality of the compounds were monitored by TLC on Silufol UV-254 plates. Preparative TLC was performed on a 5&#x02013;40 mesh silica gel, eluting with a petroleum ether&#x02013;ethyl acetate mixture.</p><p>The general procedure for the three-component one-pot cycloaddition reaction of isatins, <italic toggle="yes">&#x003b1;</italic>-amino acids and cyclopropenes was as follows: A mixture of cyclopropene (0.4 mmol), isatin (0.4 mmol) and <italic toggle="yes">&#x003b1;</italic>-amino acid (0.6 mmol) was refluxed in methanol (8 mL) for 4 h under a nitrogen atmosphere. Reaction progress was monitored by TLC. After completion of the reaction, the solvent was removed under reduced pressure. The residue was recrystallized or subjected to silica gel PTLC to obtain the pure products. The <sup>1</sup>H NMR spectra of compounds 1&#x02013;29 are presented in <xref rid="app1-pharmaceuticals-17-01582" ref-type="app">Figures S8&#x02013;S36</xref>. Spectral and physical data for all the obtained products were identical to those described by us earlier for compounds 1&#x02013;25 at [<xref rid="B39-pharmaceuticals-17-01582" ref-type="bibr">39</xref>]; for others, see [<xref rid="B49-pharmaceuticals-17-01582" ref-type="bibr">49</xref>].</p><sec><title>In Silico Analysis</title><p>The molecular descriptors of the synthesized spiro-fused [3-azabicyclo[3.1.0]hexane]oxindoles and cyclopropa[a]pyrrolizidine-2,3&#x02032;-oxindoles were determined with the widely used free online software SwissADME (<uri xlink:href="http://www.swissadme.ch/">http://www.swissadme.ch/</uri>, accessed on 12 November 2024) and analyzed according to Lipinski&#x02019;s rule of five. In all the cases, the descriptors calculation was conducted by uploading the standard smile files onto the web server.</p></sec></sec><sec id="sec3dot2-pharmaceuticals-17-01582"><title>3.2. Cell Culture and Culturing Conditions</title><p>The human erythroleukemia (K-562), cervical carcinoma (HeLa) as well as mouse colon carcinoma (CT26) cell lines were obtained from the Bank of Cell Cultures of the Institute of Cytology of the Russian Academy of Sciences; the human melanoma (Sk-mel-2) cell line was obtained from the Bank of Cell Cultures of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences. The acute T cell leukemia (Jurkat) cell line was obtained from the Bank of Cell Cultures of the Institute of Immunology of the Russian Academy of Medical Sciences. The peripheral blood mononuclear cells (PBMC) were isolated from the blood of healthy donors. K-562, Jurkat, MCF-7, PBMC and CT26 cells were grown on RPMI medium (Hyclone, GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) fetal bovine serum (Hyclone, GE Healthcare Life Sciences, Logan, UT, USA) and gentamicin (Sigma-Aldrich, St. Louis, MO, USA) at 37 &#x000b0;C in a humidified atmosphere with 5% CO<sub>2</sub>. HeLa and Sk-mel-2 cells were cultured with the same supplements and conditions in DMEM medium (Hyclone, GE Healthcare Life Sciences, Logan, UT, USA).</p></sec><sec id="sec3dot3-pharmaceuticals-17-01582"><title>3.3. Cell Proliferation Assay</title><p>To evaluate the in vitro toxicity of the compounds synthesized, cells were seeded into 96-well plates at a density of 5 &#x000d7; 10<sup>3</sup> cells per well. On the next day, the tested compounds were added to the wells at concentrations ranging from 1 to 30 &#x003bc;g/mL, followed by incubation for 1 and 3 days. Cell proliferation was determined by adding 20 &#x003bc;L of MTS reagent (BioVision, Milpitas, CA, USA) stock solution per well. The plates were incubated for 2 h at 37 &#x000b0;C in a humidified, 5% CO<sub>2</sub> atmosphere. The plates were then read at 495 nm using a plate spectrophotometer (Multiskan GO, Thermo Fisher Scientific, Waltham, MA, USA). All samples were measured in triplicate.</p></sec><sec id="sec3dot4-pharmaceuticals-17-01582"><title>3.4. Actin Cytoskeleton Staining</title><p>HeLa cells were seeded at a density of 2 &#x000d7; 10<sup>5</sup> cells per dish onto a petri dish with cover slips and incubated for 24 h. After that, cells were treated with chosen compounds (10 &#x003bc;g/mL) for 24 h. The medium was removed and cells were fixed with 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA), washed three times with PBS, and permeabilized with 0.3% Triton-X100 (Sigma-Aldrich, St. Louis, MO, USA). The cells were rinsed three times with PBS. Actin filaments (microfilaments) were stained with rhodamine&#x02013;phalloidin (Invitrogen, Carlsbad, CA, USA) at 37 &#x000b0;C for 15 min. The samples were rinsed three times with PBS, followed by embedding in Fluoroshield medium (Sigma-Aldrich, St. Louis, MO, USA). Cells were imaged using an Axio Observer Z1 confocal microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany). In each experiment, at least 30 cells were imaged. Images were analyzed by a pathologist blinded to the treatment mode used for each group using ImageJ software, 1.52v.</p></sec><sec id="sec3dot5-pharmaceuticals-17-01582"><title>3.5. Evaluation of Cell Motility by Scratch Test</title><p>Cells were seeded at a density of 5 &#x000d7; 10<sup>5</sup> cells per dish onto petri dishes and grown to confluency. A 200 &#x003bc;L pipette tip was used to make scratch wounds and detached cells were removed after that by washing with phosphate-buffered saline. Culture media was replaced with serum-free DMEM in order to inhibit cell proliferation. Compounds to be screened were added at a dose of 10 &#x003bc;g/mL to the cultures and incubated for 36 h. Different fields were analyzed by bright field, and each scratch area was photographed at 0 and 36 h. Images were captured using an Axio Observer Z1 confocal microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany). The percent of wound closure in five randomly chosen fields was calculated with ImageJ software, 1.52v.</p></sec><sec id="sec3dot6-pharmaceuticals-17-01582"><title>3.6. Cell Distribution over the Different Phases of the Cell Cycle</title><p>The distribution of K562 cells in the G0/G1-, S- and G2/M-phases of the cell cycle was obtained by quantification of DNA content using flow cytometry in DAPI-stained cells. Briefly, cells were seeded at a density of 5 &#x000d7; 10<sup>4</sup> cells per well in 24-well plates. After a 24 h incubation, cells were exposed to 5, 10 or 20 &#x003bc;g/mL of the screened compounds for another 24 h. After incubation with drugs, the cells were harvested by pipetting. This was followed by treatment with 0.2 mg/mL saponin (Fluka, Waltham, MA, USA) and 0.05 mg/mL DAPI (Thermo scientific, Rockford, IL, USA). After washing, the samples were analyzed using a standard flow cytometer (BD FACSCanto II, Becton Dickinson, San Jose, CA, USA). A total of 10,000 events were acquired for the samples. Data processing was performed using the BD FACSDiva 9.0 software.</p></sec><sec id="sec3dot7-pharmaceuticals-17-01582"><title>3.7. Statistical Analysis</title><p>Statistical processing of results was performed using Statistica 6.0. All data from the three independent experiments were used for measuring the means &#x000b1; standard deviations (mean &#x000b1; SD), which were compared using the Student&#x02019;s <italic toggle="yes">t</italic>-test or a nonparametric Wilcoxon Mann&#x02013;Whitney U test.</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceuticals-17-01582"><title>4. Conclusions</title><p>A series of heterocyclic compounds containing 3-spiro[3-azabicyclo[3.1.0]hexane]oxindole and cyclopropa[a]pyrrolizidine-2,3&#x02032;-oxindole frameworks were studied for their antiproliferative activity against the human K562, Jurkat, HeLa, Sk-mel-2, MCF-7 as well as mouse CT26 cell lines. Derivatives with the [3-azabicyclo[3.1.0]hexane]-oxindole moiety showed better antiproliferative activity as compared to cyclopropa[a]pyrrolezidine-2,3&#x02032;-oxindoles. It was found that the Jurkat cell line was the most sensitive to the screened compounds among the tested cell lines, with IC<sub>50</sub> ranging from 2 &#x000b1; 1 to 12 &#x000b1; 1 &#x003bc;M (for compounds <bold>2</bold>, <bold>4</bold>, <bold>8</bold>, <bold>17</bold>, <bold>18</bold>, <bold>22</bold>, <bold>23</bold> and <bold>24</bold> after 72 h treatment). It was noticed that products with an unsubstituted nitrogen atom in the oxindol unit were more active against all studied cell lines. At the same time, those products bearing three phenyl substituents at the cyclopropane unit were usually more effective. All the active compounds significantly reduced proliferative activity at concentrations less than 12 &#x003bc;M. It was found that compounds <bold>4</bold>, <bold>8</bold>, <bold>18</bold> and <bold>24</bold> showed antiproliferative activity against the Jurkat, K-562, HeLa and Sk-mel-2 cell lines with IC<sub>50</sub> ranging from 2 to 10 &#x003bc;M after 72 h of treatment. In agreement with the DNA cytometry studies, the tested compounds achieved significant cell-cycle perturbation with a higher accumulation of cells in SubG1 and G0/G1 phases of up to 74.0&#x02013;77.5% (as compared to 45.0% in the control sample). In agreement with confocal microscopy studies, actin filaments disappeared and granular actin was distributed diffusely in the cytoplasm of up to 38% of treated HeLa cells. Additionally, the number of HeLa cells with filopodium-like membrane protrusions was significantly reduced after treatment with some of the tested compounds (from 93% in control cells to 64% after treatment). The impact on Sk-mel-2 cells&#x02019; actin cytoskeleton structure was even greater: granular actin was distributed diffusely in the cytoplasm in up to 90% of treated cells while the number of filopodia-like deformations was reduced by up to 23%. These results indirectly suggest a decrease in cell motility. A scratch test performed on the human melanoma cell line showed that these cells did not fill the scratched strip and lost their ability to move under treatment. The obtained results support the antitumor effect of the studied compounds and encourage the extension of this study in order to improve the anticancer activity and reduce the toxicological risks of the obtained compounds.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceuticals-17-01582"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/ph17121582/s1">https://www.mdpi.com/article/10.3390/ph17121582/s1</uri>.</p><supplementary-material id="pharmaceuticals-17-01582-s001" position="float" content-type="local-data"><media xlink:href="pharmaceuticals-17-01582-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Investigation, A.A.K., S.V.S., A.I.P., A.V.S. and V.M.B.; Writing, A.I.P., A.V.S. and V.M.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on reasonable request from the corresponding authors.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-17-01582"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Tan</surname><given-names>L.</given-names></name>
<name><surname>Siu</surname><given-names>K.T.H.</given-names></name>
<name><surname>Guan</surname><given-names>X.-Y.</given-names></name>
</person-group><article-title>Exploring treatment options in cancer: Tumor treatment strategies</article-title><source>Signal Transduct. Target. Ther.</source><year>2024</year><volume>9</volume><fpage>175</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-01856-7</pub-id><pub-id pub-id-type="pmid">39013849</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-17-01582"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lahlou</surname><given-names>M.</given-names></name>
</person-group><article-title>The Success of Natural Products in Drug Discovery</article-title><source>Pharmacol. Pharm.</source><year>2013</year><volume>4</volume><fpage>17</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.4236/pp.2013.43A003</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-17-01582"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hashimoto</surname><given-names>T.</given-names></name>
<name><surname>Maruoka</surname><given-names>K.</given-names></name>
</person-group><article-title>Recent Advances of Catalytic Asymmetric 1,3-Dipolar Cycloadditions</article-title><source>Chem. Rev.</source><year>2015</year><volume>115</volume><fpage>5366</fpage><lpage>5412</lpage><pub-id pub-id-type="doi">10.1021/cr5007182</pub-id><pub-id pub-id-type="pmid">25961125</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-17-01582"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Breugst</surname><given-names>M.</given-names></name>
<name><surname>Reissig</surname><given-names>H.-U.</given-names></name>
</person-group><article-title>The Huisgen Reaction: Milestones of the 1,3-Dipolar Cycloaddition</article-title><source>Angew. Chem. Int. Ed.</source><year>2020</year><volume>59</volume><fpage>12293</fpage><lpage>12307</lpage><pub-id pub-id-type="doi">10.1002/anie.202003115</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-17-01582"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Narayan</surname><given-names>R.</given-names></name>
<name><surname>Potowski</surname><given-names>M.</given-names></name>
<name><surname>Jia</surname><given-names>Z.-J.</given-names></name>
<name><surname>Antonchick</surname><given-names>A.P.</given-names></name>
<name><surname>Waldmann</surname><given-names>H.</given-names></name>
</person-group><article-title>Catalytic Enantioselective 1,3-Dipolar Cycloadditions of Azomethine Ylides for Biology-Oriented Synthesis</article-title><source>Acc. Chem. Res.</source><year>2014</year><volume>47</volume><fpage>1296</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1021/ar400286b</pub-id><pub-id pub-id-type="pmid">24730692</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-17-01582"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arrastia</surname><given-names>I.</given-names></name>
<name><surname>Arrieta</surname><given-names>A.</given-names></name>
<name><surname>Cossio</surname><given-names>F.P.</given-names></name>
</person-group><article-title>Application of 1,3-Dipolar Reactions between Azomethine Ylides and Alkenes to the Synthesis of Catalysts and Biologically Active Compounds</article-title><source>Eur. J. Org. Chem.</source><year>2018</year><volume>2018</volume><fpage>5889</fpage><lpage>5904</lpage><pub-id pub-id-type="doi">10.1002/ejoc.201800911</pub-id><pub-id pub-id-type="pmid">30555273</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-17-01582"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Belal</surname><given-names>A.</given-names></name>
<name><surname>El-Gendy</surname><given-names>B.E.-D.M.</given-names></name>
</person-group><article-title>Pyrrolizines: Promising scaffolds for anticancer drugs</article-title><source>Bioorg. Med. Chem.</source><year>2014</year><volume>22</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2013.11.040</pub-id><pub-id pub-id-type="pmid">24331756</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-17-01582"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moreira</surname><given-names>R.</given-names></name>
<name><surname>Pereira</surname><given-names>D.M.</given-names></name>
<name><surname>Valent&#x000e3;o</surname><given-names>P.</given-names></name>
<name><surname>Andrade</surname><given-names>P.B.</given-names></name>
</person-group><article-title>Pyrrolizidine Alkaloids: Chemistry, Pharmacology, Toxicology and Food Safety</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>1668</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19061668</pub-id><pub-id pub-id-type="pmid">29874826</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-17-01582"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>P.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
<name><surname>Wei</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Zhai</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Straightforward Synthesis of Succinimide-Fused Pyrrolizidines by A Three-Component Reaction of &#x003b1;-Diketone, Amino Acid, and Maleimide</article-title><source>Synthesis</source><year>2021</year><volume>53</volume><fpage>1262</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1055/s-0040-1706608</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-17-01582"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fohlen</surname><given-names>A.</given-names></name>
<name><surname>Bordji</surname><given-names>K.</given-names></name>
<name><surname>Assenat</surname><given-names>E.</given-names></name>
<name><surname>Gongora</surname><given-names>C.</given-names></name>
<name><surname>Bazille</surname><given-names>C.</given-names></name>
<name><surname>Boulonnais</surname><given-names>J.</given-names></name>
<name><surname>Naveau</surname><given-names>M.</given-names></name>
<name><surname>Breuil</surname><given-names>C.</given-names></name>
<name><surname>P&#x000e9;r&#x000e8;s</surname><given-names>E.A.</given-names></name>
<name><surname>Bernaudin</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Anticancer Drugs for Intra-Arterial Treatment of Colorectal Cancer Liver Metastases: In-Vitro Screening after Short Exposure Time</article-title><source>Pharmaceuticals</source><year>2021</year><volume>14</volume><elocation-id>639</elocation-id><pub-id pub-id-type="doi">10.3390/ph14070639</pub-id><pub-id pub-id-type="pmid">34358065</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-17-01582"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hol</surname><given-names>W.</given-names></name>
<name><surname>Van Veen</surname><given-names>J.</given-names></name>
</person-group><article-title>Pyrrolizidine alkaloids from <italic toggle="yes">Senecio jacobaea</italic> affect fungal growth</article-title><source>J. Chem. Ecol.</source><year>2002</year><volume>28</volume><fpage>1763</fpage><lpage>1772</lpage><pub-id pub-id-type="doi">10.1023/A:1020557000707</pub-id><pub-id pub-id-type="pmid">12449504</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-17-01582"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Appadurai</surname><given-names>P.</given-names></name>
<name><surname>Rathinasamy</surname><given-names>K.</given-names></name>
</person-group><article-title>Indicine N-oxide binds to tubulin at a distinct site and inhibits the assembly of microtubules: A mechanism for its cytotoxic activity</article-title><source>Toxicol. Lett.</source><year>2014</year><volume>225</volume><fpage>66</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2013.11.030</pub-id><pub-id pub-id-type="pmid">24300171</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-17-01582"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>AbdelSamad</surname><given-names>A.L.</given-names></name>
<name><surname>El-Saadi</surname><given-names>M.T.</given-names></name>
<name><surname>Gouda</surname><given-names>A.M.</given-names></name>
<name><surname>AboulMagd</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Pyrrolizine/indolizine-bearing (un)substituted isoindole moiety: Design, synthesis, antiproliferative and MDR reversal activities, and in silico studies</article-title><source>RSC Adv.</source><year>2023</year><volume>13</volume><fpage>30753</fpage><lpage>30770</lpage><pub-id pub-id-type="doi">10.1039/D3RA05310E</pub-id><pub-id pub-id-type="pmid">37869384</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-17-01582"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sugie</surname><given-names>Y.</given-names></name>
<name><surname>Hirai</surname><given-names>H.</given-names></name>
<name><surname>Kachi-Tonai</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>Y.-J.</given-names></name>
<name><surname>Kojima</surname><given-names>Y.</given-names></name>
<name><surname>Shiomi</surname><given-names>Y.</given-names></name>
<name><surname>Kojima</surname><given-names>N.</given-names></name>
</person-group><article-title>New Pyrrolizidinone Antibiotics CJ-16,264 and CJ-16,367</article-title><source>J. Antibiot.</source><year>2001</year><volume>54</volume><fpage>917</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.54.917</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-17-01582"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abbas</surname><given-names>S.E.</given-names></name>
<name><surname>Awadallah</surname><given-names>F.M.</given-names></name>
<name><surname>Ibrahim</surname><given-names>N.A.</given-names></name>
<name><surname>Gouda</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Novel substituted and fused pyrrolizine derivatives: Synthesis, anti-inflammatory and ulcerogenecity studies</article-title><source>Eur. J. Med. Chem.</source><year>2010</year><volume>45</volume><fpage>482</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2009.10.031</pub-id><pub-id pub-id-type="pmid">19913956</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-17-01582"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qiao</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>Y.-S.</given-names></name>
<name><surname>Zeng</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>F.-L.</given-names></name>
<name><surname>Luo</surname><given-names>R.-H.</given-names></name>
<name><surname>Huang</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Y.-F.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Quan</surname><given-names>B.</given-names></name>
<name><surname>Shen</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 M<sup>pro</sup> inhibitors with antiviral activity in a transgenic mouse model</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>1374</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.1126/science.abf1611</pub-id><pub-id pub-id-type="pmid">33602867</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-17-01582"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aboelmagd</surname><given-names>M.</given-names></name>
<name><surname>Elokely</surname><given-names>K.</given-names></name>
<name><surname>Zaki</surname><given-names>M.A.</given-names></name>
<name><surname>Said</surname><given-names>A.</given-names></name>
<name><surname>Haggag</surname><given-names>E.G.</given-names></name>
<name><surname>Ross</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Anti-inflammatory of pyrrolizidine alkaloids from <italic toggle="yes">Heliotropium digynum</italic></article-title><source>Med. Chem. Res.</source><year>2018</year><volume>27</volume><fpage>1066</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1007/s00044-017-2128-y</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-17-01582"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schweizer</surname><given-names>E.</given-names></name>
<name><surname>Hoffmann-R&#x000f6;der</surname><given-names>A.</given-names></name>
<name><surname>Olsen</surname><given-names>J.A.</given-names></name>
<name><surname>Seiler</surname><given-names>P.</given-names></name>
<name><surname>Obst-Sander</surname><given-names>U.</given-names></name>
<name><surname>Wagner</surname><given-names>B.</given-names></name>
<name><surname>Kansy</surname><given-names>M.</given-names></name>
<name><surname>Banner</surname><given-names>D.W.</given-names></name>
<name><surname>Diederich</surname><given-names>F.</given-names></name>
</person-group><article-title>Multipolar interactions in the D pocket of thrombin: Large differences between tricyclic imide and lactam inhibitors</article-title><source>Org. Biomol. Chem.</source><year>2006</year><volume>4</volume><fpage>2364</fpage><lpage>2375</lpage><pub-id pub-id-type="doi">10.1039/B602585D</pub-id><pub-id pub-id-type="pmid">16763681</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-17-01582"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tanaka</surname><given-names>S.</given-names></name>
<name><surname>Honmura</surname><given-names>Y.</given-names></name>
<name><surname>Uesugi</surname><given-names>S.</given-names></name>
<name><surname>Fukushi</surname><given-names>E.</given-names></name>
<name><surname>Tanaka</surname><given-names>K.</given-names></name>
<name><surname>Maeda</surname><given-names>H.</given-names></name>
<name><surname>Kimura</surname><given-names>K.</given-names></name>
<name><surname>Nehira</surname><given-names>T.</given-names></name>
<name><surname>Hashimoto</surname><given-names>M.</given-names></name>
</person-group><article-title>Cyclohelminthol X, a Hexa-Substituted Spirocyclopropane from Helminthosporium velutinum yone96: Structural Elucidation, Electronic Circular Dichroism Analysis, and Biological Properties</article-title><source>J. Org. Chem.</source><year>2017</year><volume>82</volume><fpage>5574</fpage><lpage>5582</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.7b00393</pub-id><pub-id pub-id-type="pmid">28467078</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-17-01582"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Netz</surname><given-names>N.</given-names></name>
<name><surname>Opatz</surname><given-names>T.</given-names></name>
</person-group><article-title>A Modular Formal Total Synthesis of (&#x000b1;)-Cycloclavine</article-title><source>J. Org. Chem.</source><year>2016</year><volume>81</volume><fpage>1723</fpage><lpage>1730</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.5b02815</pub-id><pub-id pub-id-type="pmid">26811951</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-17-01582"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>M.H.</given-names></name>
<name><surname>Gordon</surname><given-names>L.A.</given-names></name>
<name><surname>Fung</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Boceprevir: A protease inhibitor for the treatment of hepatitis C</article-title><source>Clin. Ther.</source><year>2012</year><volume>34</volume><fpage>2021</fpage><lpage>2038</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2012.08.009</pub-id><pub-id pub-id-type="pmid">22975763</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-17-01582"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>P.</given-names></name>
<name><surname>Zhu</surname><given-names>C.</given-names></name>
<name><surname>Zhu</surname><given-names>R.</given-names></name>
<name><surname>Lin</surname><given-names>Z.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Jiang</surname><given-names>H.</given-names></name>
</person-group><article-title>Synthesis of 3-azabicyclo[3.1.0]hexane derivatives via palladium-catalyzed cyclopropanation of maleimides with N-tosylhydrazones: Practical and facile access to CP-866,087</article-title><source>Org. Biomol. Chem.</source><year>2017</year><volume>15</volume><fpage>1228</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1039/C6OB02137A</pub-id><pub-id pub-id-type="pmid">28094400</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-17-01582"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McHardy</surname><given-names>S.F.</given-names></name>
<name><surname>Heck</surname><given-names>S.D.</given-names></name>
<name><surname>Guediche</surname><given-names>S.</given-names></name>
<name><surname>Kalman</surname><given-names>M.</given-names></name>
<name><surname>Allen</surname><given-names>M.P.</given-names></name>
<name><surname>Tu</surname><given-names>M.</given-names></name>
<name><surname>Bryce</surname><given-names>D.K.</given-names></name>
<name><surname>Schmidt</surname><given-names>A.W.</given-names></name>
<name><surname>Vanase-Frawley</surname><given-names>M.</given-names></name>
<name><surname>Callegari</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Discovery of CP-866,087, a mu opioid receptor antagonist for the treatment of alcohol abuse and dependence</article-title><source>Med. Chem. Commun.</source><year>2011</year><volume>2</volume><fpage>1001</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1039/c1md00164g</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-17-01582"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lunn</surname><given-names>G.</given-names></name>
<name><surname>Banks</surname><given-names>B.J.</given-names></name>
<name><surname>Crook</surname><given-names>R.</given-names></name>
<name><surname>Feeder</surname><given-names>N.</given-names></name>
<name><surname>Pettman</surname><given-names>A.</given-names></name>
<name><surname>Sabnis</surname><given-names>Y.</given-names></name>
</person-group><article-title>Discovery and synthesis of a new class of opioid ligand having a 3-azabicyclo[3.1.0]hexane core. An example of a &#x02018;magic methyl&#x02019; giving a 35-fold improvement in binding</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2011</year><volume>21</volume><fpage>4608</fpage><lpage>4611</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2011.05.132</pub-id><pub-id pub-id-type="pmid">21737265</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-17-01582"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
<name><surname>Zheng</surname><given-names>Z.</given-names></name>
<name><surname>Ye</surname><given-names>F.</given-names></name>
<name><surname>Ma</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>Z.</given-names></name>
<name><surname>Bai</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
</person-group><article-title>Highly efficient desymmetrization of cyclopropenes to azabicyclo[3.1.0]hexanes with five continuous stereogenic centers by copper-catalyzed [3 + 2] cycloadditions</article-title><source>Org. Chem. Front.</source><year>2018</year><volume>5</volume><fpage>2759</fpage><lpage>2764</lpage><pub-id pub-id-type="doi">10.1039/C8QO00761F</pub-id></element-citation></ref><ref id="B26-pharmaceuticals-17-01582"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Runyon</surname><given-names>S.P.</given-names></name>
<name><surname>Kormos</surname><given-names>C.M.</given-names></name>
<name><surname>Gichinga</surname><given-names>M.G.</given-names></name>
<name><surname>Mascarella</surname><given-names>S.W.</given-names></name>
<name><surname>Navarro</surname><given-names>H.A.</given-names></name>
<name><surname>Deschamps</surname><given-names>J.R.</given-names></name>
<name><surname>Imler</surname><given-names>G.H.</given-names></name>
<name><surname>Carroll</surname><given-names>F.I.</given-names></name>
</person-group><article-title>Design, synthesis, and biological evaluation of structurally rigid analogues of 4-(3-hydroxyphenyl)piperidine opioid receptor antagonists</article-title><source>J. Org. Chem.</source><year>2016</year><volume>81</volume><fpage>10383</fpage><lpage>10391</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.6b01366</pub-id><pub-id pub-id-type="pmid">27462910</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-17-01582"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Topczewski</surname><given-names>J.J.</given-names></name>
<name><surname>Cabrera</surname><given-names>P.J.</given-names></name>
<name><surname>Saper</surname><given-names>N.I.</given-names></name>
<name><surname>Sanford</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Palladium-catalysed transannular C&#x02013;H functionalization of alicyclic amines</article-title><source>Nature</source><year>2016</year><volume>531</volume><fpage>220</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1038/nature16957</pub-id><pub-id pub-id-type="pmid">26886789</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-17-01582"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moffat</surname><given-names>D.</given-names></name>
<name><surname>Patel</surname><given-names>S.</given-names></name>
<name><surname>Day</surname><given-names>F.</given-names></name>
<name><surname>Belfield</surname><given-names>A.</given-names></name>
<name><surname>Donald</surname><given-names>A.</given-names></name>
<name><surname>Rowlands</surname><given-names>M.</given-names></name>
<name><surname>Wibawa</surname><given-names>J.</given-names></name>
<name><surname>Brotherton</surname><given-names>D.</given-names></name>
<name><surname>Stimson</surname><given-names>L.</given-names></name>
<name><surname>Clark</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor</article-title><source>J. Med. Chem.</source><year>2010</year><volume>53</volume><fpage>8663</fpage><lpage>8678</lpage><pub-id pub-id-type="doi">10.1021/jm101177s</pub-id><pub-id pub-id-type="pmid">21080647</pub-id>
</element-citation></ref><ref id="B29-pharmaceuticals-17-01582"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>S.</given-names></name>
<name><surname>Meilandt</surname><given-names>W.J.</given-names></name>
<name><surname>Erickson</surname><given-names>R.I.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Deshmukh</surname><given-names>G.</given-names></name>
<name><surname>Estrada</surname><given-names>A.A.</given-names></name>
<name><surname>Fuji</surname><given-names>R.N.</given-names></name>
<name><surname>Gibbons</surname><given-names>P.</given-names></name>
<name><surname>Gustafson</surname><given-names>A.</given-names></name>
<name><surname>Harris</surname><given-names>S.F.</given-names></name>
<etal/>
</person-group><article-title>Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer&#x02019;s Disease</article-title><source>J. Med. Chem.</source><year>2017</year><volume>60</volume><fpage>8083</fpage><lpage>8102</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00843</pub-id><pub-id pub-id-type="pmid">28929759</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-17-01582"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Skepper</surname><given-names>C.K.</given-names></name>
<name><surname>Armstrong</surname><given-names>D.</given-names></name>
<name><surname>Balibar</surname><given-names>C.J.</given-names></name>
<name><surname>Bauer</surname><given-names>D.</given-names></name>
<name><surname>Bellamacina</surname><given-names>C.</given-names></name>
<name><surname>Benton</surname><given-names>B.M.</given-names></name>
<name><surname>Bussiere</surname><given-names>D.</given-names></name>
<name><surname>De Pascale</surname><given-names>G.</given-names></name>
<name><surname>De Vicente</surname><given-names>J.</given-names></name>
<name><surname>Dean</surname><given-names>C.R.</given-names></name>
<etal/>
</person-group><article-title>Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria</article-title><source>J. Med. Chem.</source><year>2020</year><volume>63</volume><fpage>7773</fpage><lpage>7816</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00347</pub-id><pub-id pub-id-type="pmid">32634310</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-17-01582"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Komine</surname><given-names>T.</given-names></name>
<name><surname>Kojima</surname><given-names>A.</given-names></name>
<name><surname>Asahina</surname><given-names>Y.</given-names></name>
<name><surname>Saito</surname><given-names>T.</given-names></name>
<name><surname>Takano</surname><given-names>H.</given-names></name>
<name><surname>Shibue</surname><given-names>T.</given-names></name>
<name><surname>Fukuda</surname><given-names>Y.</given-names></name>
</person-group><article-title>Synthesis and Structure&#x02212;Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials</article-title><source>J. Med. Chem.</source><year>2008</year><volume>51</volume><fpage>6558</fpage><lpage>6562</lpage><pub-id pub-id-type="doi">10.1021/jm800800c</pub-id><pub-id pub-id-type="pmid">18826297</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-17-01582"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Appel</surname><given-names>N.M.</given-names></name>
<name><surname>Li</surname><given-names>S.H.</given-names></name>
<name><surname>Holmes</surname><given-names>T.H.</given-names></name>
<name><surname>Acri</surname><given-names>J.B.</given-names></name>
</person-group><article-title>Dopamine D3 receptor antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2015</year><volume>354</volume><fpage>484</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1124/jpet.115.224121</pub-id><pub-id pub-id-type="pmid">26177654</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-17-01582"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>J.-Y.</given-names></name>
<name><surname>Zhou</surname><given-names>S.-W.</given-names></name>
</person-group><article-title>Isorhynchophylline: A plant alkaloid with therapeutic potential for cardiovascular and central nervous system diseases</article-title><source>Fitoterapia</source><year>2012</year><volume>83</volume><fpage>617</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2012.02.010</pub-id><pub-id pub-id-type="pmid">22406453</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-17-01582"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>S.</given-names></name>
</person-group><article-title>Antihypertensive and neuroprotective activities of rhynchophylline: The role of rhynchophylline in neurotransmission and ion channel activity</article-title><source>J. Ethnopharmacol.</source><year>2010</year><volume>132</volume><fpage>15</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2010.08.041</pub-id><pub-id pub-id-type="pmid">20736055</pub-id>
</element-citation></ref><ref id="B35-pharmaceuticals-17-01582"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ye</surname><given-names>N.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Wold</surname><given-names>E.A.</given-names></name>
<name><surname>Shi</surname><given-names>P.-Y.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
</person-group><article-title>Therapeutic potential of spirooxindoles as antiviral agents</article-title><source>ACS Infect. Dis.</source><year>2016</year><volume>2</volume><fpage>382</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.6b00041</pub-id><pub-id pub-id-type="pmid">27627626</pub-id>
</element-citation></ref><ref id="B36-pharmaceuticals-17-01582"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>B.</given-names></name>
<name><surname>Yu</surname><given-names>D.-Q.</given-names></name>
<name><surname>Liu</surname><given-names>H.-M.</given-names></name>
</person-group><article-title>Spirooxindoles: Promising scaffolds for anticancer agents</article-title><source>Eur. J. Med. Chem.</source><year>2015</year><volume>97</volume><fpage>673</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2014.06.056</pub-id><pub-id pub-id-type="pmid">24994707</pub-id>
</element-citation></ref><ref id="B37-pharmaceuticals-17-01582"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>S.</given-names></name>
<name><surname>Sun</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Lu</surname><given-names>J.</given-names></name>
<name><surname>McEachern</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
</person-group><article-title>A Potent Small-Molecule Inhibitor of the MDM2&#x02013;p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice</article-title><source>J. Med. Chem.</source><year>2013</year><volume>56</volume><fpage>5553</fpage><lpage>5561</lpage><pub-id pub-id-type="doi">10.1021/jm4005708</pub-id><pub-id pub-id-type="pmid">23786219</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-17-01582"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Filatov</surname><given-names>A.S.</given-names></name>
<name><surname>Selivanov</surname><given-names>S.I.</given-names></name>
<name><surname>Shmakov</surname><given-names>S.V.</given-names></name>
<name><surname>Larina</surname><given-names>A.G.</given-names></name>
<name><surname>Boitsov</surname><given-names>V.M.</given-names></name>
<name><surname>Stepakov</surname><given-names>A.V.</given-names></name>
</person-group><article-title>An Experimental and Theoretical Study of the 1,3-Dipolar Cycloaddition of Alloxan-Derived Azomethine Ylides to Cyclopropenes</article-title><source>Synthesis</source><year>2022</year><volume>54</volume><fpage>1803</fpage><lpage>1816</lpage><pub-id pub-id-type="doi">10.1055/a-1700-3115</pub-id></element-citation></ref><ref id="B39-pharmaceuticals-17-01582"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Filatov</surname><given-names>A.S.</given-names></name>
<name><surname>Knyazev</surname><given-names>N.A.</given-names></name>
<name><surname>Molchanov</surname><given-names>A.P.</given-names></name>
<name><surname>Panikorovsky</surname><given-names>T.L.</given-names></name>
<name><surname>Kostikov</surname><given-names>R.R.</given-names></name>
<name><surname>Larina</surname><given-names>A.G.</given-names></name>
<name><surname>Boitsov</surname><given-names>V.M.</given-names></name>
<name><surname>Stepakov</surname><given-names>A.V.</given-names></name>
</person-group><article-title>Synthesis of Functionalized 3-Spiro[cyclopropa[<italic toggle="yes">a</italic>]pyrrolizine]- and 3-Spiro [3-azabicyclo[3.1.0]hexane]oxindoles from Cyclopropenes and Azomethine Ylides via [3 + 2]-Cycloaddition</article-title><source>J. Org. Chem.</source><year>2017</year><volume>82</volume><fpage>959</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.6b02505</pub-id><pub-id pub-id-type="pmid">28004934</pub-id>
</element-citation></ref><ref id="B40-pharmaceuticals-17-01582"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Filatov</surname><given-names>A.S.</given-names></name>
<name><surname>Knyazev</surname><given-names>N.A.</given-names></name>
<name><surname>Shmakov</surname><given-names>S.V.</given-names></name>
<name><surname>Bogdanov</surname><given-names>A.A.</given-names></name>
<name><surname>Ryazantsev</surname><given-names>M.N.</given-names></name>
<name><surname>Shtyrov</surname><given-names>A.A.</given-names></name>
<name><surname>Starova</surname><given-names>G.L.</given-names></name>
<name><surname>Molchanov</surname><given-names>A.P.</given-names></name>
<name><surname>Larina</surname><given-names>A.G.</given-names></name>
<name><surname>Boitsov</surname><given-names>V.M.</given-names></name>
<etal/>
</person-group><article-title>Concise Synthesis of Tryptanthrin Spiro Analogues with In Vitro Antitumor Activity Based on One-Pot, Three-Component 1,3-Dipolar Cycloaddition of Azomethine Ylides to Cyclopropenes</article-title><source>Synthesis</source><year>2019</year><volume>51</volume><fpage>713</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1055/s-0037-1611059</pub-id></element-citation></ref><ref id="B41-pharmaceuticals-17-01582"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Filatov</surname><given-names>A.S.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Khoroshilova</surname><given-names>O.V.</given-names></name>
<name><surname>Lozovskiy</surname><given-names>S.V.</given-names></name>
<name><surname>Larina</surname><given-names>A.G.</given-names></name>
<name><surname>Boitsov</surname><given-names>V.M.</given-names></name>
<name><surname>Stepakov</surname><given-names>A.V.</given-names></name>
</person-group><article-title>Stereo- and Regioselective 1,3-Dipolar Cycloaddition of the Stable Ninhydrin-Derived Azomethine Ylide to Cyclopropenes: Trapping of Unstable Cyclopropene Dipolarophiles</article-title><source>J. Org. Chem.</source><year>2019</year><volume>84</volume><fpage>7017</fpage><lpage>7036</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.9b00753</pub-id><pub-id pub-id-type="pmid">31066276</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-17-01582"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Selivanov</surname><given-names>S.I.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Filatov</surname><given-names>A.S.</given-names></name>
<name><surname>Stepakov</surname><given-names>A.V.</given-names></name>
</person-group><article-title>NMR Study of Spatial Structure and Internal Dynamic of Adducts of Ninhydrin-Derived Azomethine Ylide with Cyclopropenes</article-title><source>Appl. Magn. Reson.</source><year>2020</year><volume>51</volume><fpage>165</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1007/s00723-019-01178-w</pub-id></element-citation></ref><ref id="B43-pharmaceuticals-17-01582"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Filatov</surname><given-names>A.S.</given-names></name>
<name><surname>Lozovskiy</surname><given-names>S.V.</given-names></name>
<name><surname>Shmakov</surname><given-names>S.V.</given-names></name>
<name><surname>Khoroshilova</surname><given-names>O.V.</given-names></name>
<name><surname>Larina</surname><given-names>A.G.</given-names></name>
<name><surname>Selivanov</surname><given-names>S.I.</given-names></name>
<name><surname>Boitsov</surname><given-names>V.M.</given-names></name>
<name><surname>Stepakov</surname><given-names>A.V.</given-names></name>
</person-group><article-title>Construction of Spiro[3-azabicyclo[3.1.0]hexanes] via 1,3-Dipolar Cycloaddition of 1,2-Diphenylcyclopropenes to Ninhydrin-Derived Azomethine Ylides</article-title><source>Synthesis</source><year>2021</year><volume>53</volume><fpage>2114</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1055/a-1360-9716</pub-id></element-citation></ref><ref id="B44-pharmaceuticals-17-01582"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Filatov</surname><given-names>A.S.</given-names></name>
<name><surname>Khoroshilova</surname><given-names>O.V.</given-names></name>
<name><surname>Larina</surname><given-names>A.G.</given-names></name>
<name><surname>Boitsov</surname><given-names>V.M.</given-names></name>
<name><surname>Stepakov</surname><given-names>A.V.</given-names></name>
</person-group><article-title>Synthesis of bis-spirocyclic derivatives of 3-azabicyclo[3.1.0]hexane via cyclopropene cycloadditions to the stable azomethine ylide derived from Ruhemann&#x02019;s purple</article-title><source>Beilstein J. Org. Chem.</source><year>2022</year><volume>18</volume><fpage>769</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.3762/bjoc.18.77</pub-id><pub-id pub-id-type="pmid">35859623</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-17-01582"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Filatov</surname><given-names>A.S.</given-names></name>
<name><surname>Knyazev</surname><given-names>N.A.</given-names></name>
<name><surname>Ryazantsev</surname><given-names>M.N.</given-names></name>
<name><surname>Suslonov</surname><given-names>V.V.</given-names></name>
<name><surname>Larina</surname><given-names>A.G.</given-names></name>
<name><surname>Molchanov</surname><given-names>A.P.</given-names></name>
<name><surname>Kostikov</surname><given-names>R.R.</given-names></name>
<name><surname>Boitsov</surname><given-names>V.M.</given-names></name>
<name><surname>Stepakov</surname><given-names>A.V.</given-names></name>
</person-group><article-title>A highly diastereoselective one-pot three-component 1,3-dipolar cycloaddition of cyclopropenes with azomethine ylides generated from 11<italic toggle="yes">H</italic>-indeno[1,2-<italic toggle="yes">b</italic>]-quinoxalin-11-ones</article-title><source>Org. Chem. Front.</source><year>2018</year><volume>5</volume><fpage>595</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1039/C7QO00888K</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-17-01582"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Knyazev</surname><given-names>N.A.</given-names></name>
<name><surname>Shmakov</surname><given-names>S.V.</given-names></name>
<name><surname>Pechkovskaya</surname><given-names>S.A.</given-names></name>
<name><surname>Filatov</surname><given-names>A.S.</given-names></name>
<name><surname>Stepakov</surname><given-names>A.V.</given-names></name>
<name><surname>Boitsov</surname><given-names>V.M.</given-names></name>
<name><surname>Filatova</surname><given-names>N.A.</given-names></name>
</person-group><article-title>Identification of Spiro-Fused 3-Azabicyclo[3.1.0]hexane]oxindoles as Potential Antitumor Agents: Initial In Vitro Evaluation of Anti-Proliferative Effect and Actin Cytoskeleton Transformation in 3T3 and 3T3-SV40 Fibroblast</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>8264</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22158264</pub-id><pub-id pub-id-type="pmid">34361029</pub-id>
</element-citation></ref><ref id="B47-pharmaceuticals-17-01582"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Latypova</surname><given-names>D.K.</given-names></name>
<name><surname>Shmakov</surname><given-names>S.V.</given-names></name>
<name><surname>Pechkovskaya</surname><given-names>S.A.</given-names></name>
<name><surname>Filatov</surname><given-names>A.S.</given-names></name>
<name><surname>Stepakov</surname><given-names>A.V.</given-names></name>
<name><surname>Knyazev</surname><given-names>N.A.</given-names></name>
<name><surname>Boitsov</surname><given-names>V.M.</given-names></name>
</person-group><article-title>Identification of Spiro-Fused Pyrrolo[3,4-<italic toggle="yes">a</italic>]pyrrolizines and Tryptanthrines as Potential Antitumor Agents: Synthesis and In Vitro Evaluation</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>11997</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222111997</pub-id><pub-id pub-id-type="pmid">34769424</pub-id>
</element-citation></ref><ref id="B48-pharmaceuticals-17-01582"><label>48.</label><element-citation publication-type="confproc"><person-group person-group-type="author">
<name><surname>Kornev</surname><given-names>A.</given-names></name>
<name><surname>Shmakov</surname><given-names>S.</given-names></name>
<name><surname>Klyuchnikov</surname><given-names>A.</given-names></name>
<name><surname>Artemov</surname><given-names>A.V.</given-names></name>
<name><surname>Stepakov</surname><given-names>A.</given-names></name>
<name><surname>Boitsov</surname><given-names>V.</given-names></name>
</person-group><article-title>Study of cytotoxicity of spiro-fused [3-azabicyclo[3.1.0]hexane]oxindoles against tumor cell lines</article-title><source>Proceedings of the 8th International Electronic Conference on Medicinal Chemistry</source><conf-loc>Basel, Switzerland</conf-loc><conf-date>1&#x02013;30 November 2022</conf-date><pub-id pub-id-type="doi">10.3390/ECMC2022-13653</pub-id></element-citation></ref><ref id="B49-pharmaceuticals-17-01582"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pronina</surname><given-names>Y.A.</given-names></name>
<name><surname>Viktorov</surname><given-names>N.B.</given-names></name>
<name><surname>Selivanov</surname><given-names>S.I.</given-names></name>
<name><surname>Kornev</surname><given-names>A.A.</given-names></name>
<name><surname>Ponyaev</surname><given-names>A.I.</given-names></name>
<name><surname>Boitsov</surname><given-names>V.M.</given-names></name>
<name><surname>Stepakov</surname><given-names>A.V.</given-names></name>
</person-group><article-title>Organocatalytic Diastereoselective Synthesis of Spiro[3-azabicyclo[3.1.0]-hexanes] <italic toggle="yes">via</italic>1,3-Dipolar Cycloaddition of Azomethine Ylides with Cyclopropenes</article-title><source>Russ. J. Gen. Chem.</source><year>2024</year><volume>94</volume><fpage>804</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1134/S107036322404008X</pub-id></element-citation></ref><ref id="B50-pharmaceuticals-17-01582"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tojkander</surname><given-names>S.</given-names></name>
<name><surname>Gateva</surname><given-names>G.</given-names></name>
<name><surname>Lappalainen</surname><given-names>P.</given-names></name>
</person-group><article-title>Actin stress fibers&#x02014;Assembly, dynamics and biological roles</article-title><source>J. Cell. Sci.</source><year>2012</year><volume>125</volume><fpage>1855</fpage><lpage>1864</lpage><pub-id pub-id-type="doi">10.1242/jcs.098087</pub-id><pub-id pub-id-type="pmid">22544950</pub-id>
</element-citation></ref><ref id="B51-pharmaceuticals-17-01582"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sahai</surname><given-names>E.</given-names></name>
<name><surname>Marshall</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis</article-title><source>Nat. Cell. Biol.</source><year>2003</year><volume>5</volume><fpage>711</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1038/ncb1019</pub-id><pub-id pub-id-type="pmid">12844144</pub-id>
</element-citation></ref><ref id="B52-pharmaceuticals-17-01582"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spano</surname><given-names>A.</given-names></name>
<name><surname>Monaco</surname><given-names>G.</given-names></name>
<name><surname>Barni</surname><given-names>S.</given-names></name>
<name><surname>Sciola</surname><given-names>L.</given-names></name>
</person-group><article-title>Cisplatin treatment of NIH/3T3 cultures induces a form of autophagic death in polyploid cells</article-title><source>Histol. Histopathol.</source><year>2008</year><volume>23</volume><fpage>717</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.14670/HH-23.717</pub-id><pub-id pub-id-type="pmid">18366010</pub-id>
</element-citation></ref><ref id="B53-pharmaceuticals-17-01582"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bonello</surname><given-names>T.T.</given-names></name>
<name><surname>Stehn</surname><given-names>J.R.</given-names></name>
<name><surname>Gunning</surname><given-names>P.W.</given-names></name>
</person-group><article-title>New approaches to targeting the actin cytoskeleton for chemotherapy</article-title><source>Future Med. Chem.</source><year>2009</year><volume>1</volume><fpage>1311</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.4155/fmc.09.99</pub-id><pub-id pub-id-type="pmid">21426105</pub-id>
</element-citation></ref><ref id="B54-pharmaceuticals-17-01582"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Northcott</surname><given-names>J.M.</given-names></name>
<name><surname>Dean</surname><given-names>I.S.</given-names></name>
<name><surname>Mouw</surname><given-names>J.K.</given-names></name>
<name><surname>Weaver</surname><given-names>V.M.</given-names></name>
</person-group><article-title>Feeling Stress: The Mechanics of Cancer Progression and Aggression</article-title><source>Front. Cell. Dev. Biol.</source><year>2018</year><volume>6</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2018.00017</pub-id><pub-id pub-id-type="pmid">29541636</pub-id>
</element-citation></ref><ref id="B55-pharmaceuticals-17-01582"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Mouw</surname><given-names>J.K.</given-names></name>
<name><surname>Weaver</surname><given-names>V.M.</given-names></name>
</person-group><article-title>Forcing form and function: Biomechanical regulation of tumor evolution</article-title><source>Trends Cell. Biol.</source><year>2011</year><volume>21</volume><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2010.08.015</pub-id><pub-id pub-id-type="pmid">20870407</pub-id>
</element-citation></ref><ref id="B56-pharmaceuticals-17-01582"><label>56.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Brayford</surname><given-names>S.</given-names></name>
<name><surname>Schevzov</surname><given-names>G.</given-names></name>
<name><surname>Vos</surname><given-names>J.</given-names></name>
<name><surname>Gunning</surname><given-names>P.</given-names></name>
</person-group><article-title>The Role of the Actin Cytoskeleton in Cancer and Its Potential Use as a Therapeutic Target</article-title><source>The Cytoskeleton in Health and Disease</source><person-group person-group-type="editor">
<name><surname>Schatten</surname><given-names>H.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2015</year><pub-id pub-id-type="doi">10.1007/978-1-4939-2904-7_16</pub-id></element-citation></ref><ref id="B57-pharmaceuticals-17-01582"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Babushkina</surname><given-names>A.A.</given-names></name>
<name><surname>Dogadina</surname><given-names>A.V.</given-names></name>
<name><surname>Egorov</surname><given-names>D.M.</given-names></name>
<name><surname>Piterskaia</surname><given-names>J.L.</given-names></name>
<name><surname>Shtro</surname><given-names>A.A.</given-names></name>
<name><surname>Nikolaeva</surname><given-names>Y.V.</given-names></name>
<name><surname>Galochkina</surname><given-names>A.V.</given-names></name>
<name><surname>Kornev</surname><given-names>A.A.</given-names></name>
<name><surname>Boitsov</surname><given-names>V.M.</given-names></name>
</person-group><article-title>Efficient synthesis and evaluation of antiviral and antitumor activity of novel 3-phosphonylated thiazolo[3,2-a]oxopyrimidines</article-title><source>Med. Chem. Res.</source><year>2021</year><volume>30</volume><fpage>2203</fpage><lpage>2215</lpage><pub-id pub-id-type="doi">10.1007/s00044-021-02801-x</pub-id></element-citation></ref><ref id="B58-pharmaceuticals-17-01582"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aseervatham</surname><given-names>J.</given-names></name>
</person-group><article-title>Cytoskeletal Remodeling in Cancer</article-title><source>Biology</source><year>2020</year><volume>9</volume><elocation-id>385</elocation-id><pub-id pub-id-type="doi">10.3390/biology9110385</pub-id><pub-id pub-id-type="pmid">33171868</pub-id>
</element-citation></ref><ref id="B59-pharmaceuticals-17-01582"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stuelten</surname><given-names>C.H.</given-names></name>
<name><surname>Parent</surname><given-names>C.A.</given-names></name>
<name><surname>Montell</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Cell motility in cancer invasion and metastasis: Insights from simple model organisms</article-title><source>Nat. Rev. Cancer</source><year>2018</year><volume>18</volume><fpage>296</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/nrc.2018.15</pub-id><pub-id pub-id-type="pmid">29546880</pub-id>
</element-citation></ref><ref id="B60-pharmaceuticals-17-01582"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaffer</surname><given-names>C.L.</given-names></name>
<name><surname>Weinberg</surname><given-names>R.A.</given-names></name>
</person-group><article-title>A Perspective on Cancer Cell Metastasis</article-title><source>Science</source><year>2011</year><volume>331</volume><fpage>1559</fpage><lpage>1564</lpage><pub-id pub-id-type="doi">10.1126/science.1203543</pub-id><pub-id pub-id-type="pmid">21436443</pub-id>
</element-citation></ref><ref id="B61-pharmaceuticals-17-01582"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Breslow</surname><given-names>R.</given-names></name>
<name><surname>Chang</surname><given-names>H.W.</given-names></name>
</person-group><article-title>Triarylcyclopropenium Ions. Synthesis and Stability in the Phenyl p-Anisyl Series</article-title><source>J. Am. Chem. Soc.</source><year>1961</year><volume>83</volume><fpage>2367</fpage><lpage>2375</lpage><pub-id pub-id-type="doi">10.1021/ja01471a031</pub-id></element-citation></ref><ref id="B62-pharmaceuticals-17-01582"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Padwa</surname><given-names>A.</given-names></name>
<name><surname>Blacklock</surname><given-names>T.J.</given-names></name>
<name><surname>Getman</surname><given-names>D.</given-names></name>
<name><surname>Hatanaka</surname><given-names>N.</given-names></name>
<name><surname>Loza</surname><given-names>R.</given-names></name>
</person-group><article-title>Photochemical transformations of small ring compounds. 95. The problem of regioselectivity in the photochemical ring-opening reaction of 3-phenyl- and 3-vinyl-substituted cyclopropenes to indenes and 1,3-cyclopentadienes</article-title><source>J. Org. Chem.</source><year>1978</year><volume>43</volume><fpage>1481</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1021/jo00402a002</pub-id></element-citation></ref><ref id="B63-pharmaceuticals-17-01582"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gilbertson</surname><given-names>R.D.</given-names></name>
<name><surname>Weakley</surname><given-names>T.J.R.</given-names></name>
<name><surname>Haley</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Preparation, X-ray Crystal Structures, and Reactivity of Alkynylcyclopropenylium Salts</article-title><source>J. Org. Chem.</source><year>2000</year><volume>65</volume><fpage>1422</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1021/jo9915372</pub-id><pub-id pub-id-type="pmid">10814104</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-17-01582-f001"><label>Figure 1</label><caption><p>Selected examples of biologically active 1-azabicyclo[3.3.0]octanes (pyrrolizines or pyrrolizidines), 3-azabicyclo[3.1.0]hexanes and spiro[pyrrolidine-3,3&#x02032;-oxindoles], based on the studies by Fohlen et al. (2021) [<xref rid="B10-pharmaceuticals-17-01582" ref-type="bibr">10</xref>], Appadurai et al. (2014) [<xref rid="B12-pharmaceuticals-17-01582" ref-type="bibr">12</xref>], AbdelSamad et al. (2023) [<xref rid="B13-pharmaceuticals-17-01582" ref-type="bibr">13</xref>], Sugie et al. (2001) [<xref rid="B14-pharmaceuticals-17-01582" ref-type="bibr">14</xref>], Tanaka et al. (2017) [<xref rid="B19-pharmaceuticals-17-01582" ref-type="bibr">19</xref>], Chang et al. (2012) [<xref rid="B21-pharmaceuticals-17-01582" ref-type="bibr">21</xref>], McHardy et al. (2011) [<xref rid="B23-pharmaceuticals-17-01582" ref-type="bibr">23</xref>], Moffat et al. (2010) [<xref rid="B28-pharmaceuticals-17-01582" ref-type="bibr">28</xref>], Yu et al. (2015) [<xref rid="B36-pharmaceuticals-17-01582" ref-type="bibr">36</xref>] and Zhao et al. (2013) [<xref rid="B37-pharmaceuticals-17-01582" ref-type="bibr">37</xref>].</p></caption><graphic xlink:href="pharmaceuticals-17-01582-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01582-f002"><label>Figure 2</label><caption><p>Cytotoxicity of racemic spiro-adducts against the K562 cell line for 24 h (<bold>A</bold>) and 72 h (<bold>B</bold>).</p></caption><graphic xlink:href="pharmaceuticals-17-01582-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01582-f003"><label>Figure 3</label><caption><p>Cytotoxicity of racemic spiro-adducts against the HeLa cell line for 24 h (<bold>A</bold>) and 72 h (<bold>B</bold>).</p></caption><graphic xlink:href="pharmaceuticals-17-01582-g003" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01582-f004"><label>Figure 4</label><caption><p>Cytotoxicity of selected racemic spiro-adducts against the Jurkat cell line for 24 h (<bold>A</bold>) and 72 h (<bold>B</bold>).</p></caption><graphic xlink:href="pharmaceuticals-17-01582-g004" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01582-f005"><label>Figure 5</label><caption><p>Cytotoxicity of racemic spiro-adducts against the Sk-mel-2 cell line for 24 h (<bold>A</bold>) and 72 h (<bold>B</bold>).</p></caption><graphic xlink:href="pharmaceuticals-17-01582-g005" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01582-f006"><label>Figure 6</label><caption><p>Cytotoxicity of selected racemic spiro-adducts against the MCF-7 cell line for 24 h (<bold>A</bold>) and 72 h (<bold>B</bold>).</p></caption><graphic xlink:href="pharmaceuticals-17-01582-g006" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01582-f007"><label>Figure 7</label><caption><p>Cytotoxicity of selected racemic spiro-adducts against the CT26 cell line for 24 h (<bold>A</bold>) and 72 h (<bold>B</bold>).</p></caption><graphic xlink:href="pharmaceuticals-17-01582-g007" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01582-f008"><label>Figure 8</label><caption><p>State of actin cytoskeleton of HeLa cells after treatment with compounds <bold>2</bold>, <bold>4</bold>, <bold>8</bold>, <bold>17</bold>, <bold>18</bold>, <bold>22</bold> and <bold>24</bold> (10 &#x003bc;g/mL). (<bold>A</bold>) Images demonstrating the different stages of the cell actin cytoskeleton. (<bold>B</bold>) Histograms demonstrating the percentage of cells with filopodia-like deformations. (<bold>C</bold>) Histograms demonstrating the percentage of cells with normal stress fibers.</p></caption><graphic xlink:href="pharmaceuticals-17-01582-g008a" position="float"/><graphic xlink:href="pharmaceuticals-17-01582-g008b" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01582-f009"><label>Figure 9</label><caption><p>State of actin cytoskeleton of Sk-mel-2 cells after treatment with compounds <bold>2</bold>, <bold>4</bold>, <bold>8</bold>, <bold>11</bold>, <bold>17</bold> and <bold>18</bold> (10 &#x003bc;g/mL). (<bold>A</bold>) Images demonstrating the different stages of the cell actin cytoskeleton. (<bold>B</bold>) Histograms demonstrating the percentage of cells with filopodia-like deformations. (<bold>C</bold>) Histograms demonstrating the percentage of cells with normal stress fibers.</p></caption><graphic xlink:href="pharmaceuticals-17-01582-g009" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01582-f010"><label>Figure 10</label><caption><p>Microscopic images of the Sk-mel-2 cell wound area in the scratch assay and wound area (%) in the scratch assay after 36 h incubation with spiro-fused [3-azabicyclo[3.1.0]hexane]oxindoles <bold>4</bold>, <bold>11</bold>, <bold>12</bold>, <bold>18</bold>, <bold>24</bold> and cyclopropa[a]pyrrolizidine-2,3&#x02032;-oxindole <bold>2</bold> (10 &#x003bc;g/mL). * <italic toggle="yes">p</italic> value &#x0003c; 0.05.</p></caption><graphic xlink:href="pharmaceuticals-17-01582-g010" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01582-f011"><label>Figure 11</label><caption><p>The effect of cycloadducts <bold>2</bold>, <bold>4</bold>, <bold>8</bold>, <bold>17</bold>, <bold>18</bold> at a concentration of 10 &#x003bc;g/mL on the distribution of <bold>K562</bold> cells in the cell cycle.</p></caption><graphic xlink:href="pharmaceuticals-17-01582-g011" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-17-01582-t001"><object-id pub-id-type="pii">pharmaceuticals-17-01582-t001_Table 1</object-id><label>Table 1</label><caption><p>Synthesis of spiro-adducts via three-component one-pot cycloaddition reactions of cyclopropenes, isatines and <italic toggle="yes">&#x003b1;</italic>-amino acids <sup>a,b,c</sup>.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-17-01582-i001.jpg"/>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-17-01582-i002.jpg"/>
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Reactions of cyclopropene (0.4 mmol), isatine (0.4 mmol) and <italic toggle="yes">&#x003b1;</italic>-amino acid (0.6 mmol) were carried out in methanol (8 mL) under reflux for 4 h under a nitrogen atmosphere. <sup>b</sup> Isolated yield. <sup>c</sup> The <italic toggle="yes">dr</italic> values were determined by <sup>1</sup>H NMR of the crude mixture.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-17-01582-t002"><object-id pub-id-type="pii">pharmaceuticals-17-01582-t002_Table 2</object-id><label>Table 2</label><caption><p>Physicochemical profiles of compounds according to Lipinski&#x02019;s rule of five.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MW</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">nHBD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">nHBA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Log P</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">nRotB</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TPSA, &#x000c5;<sup>2</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N<sub>Violation</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Meets Lipinski&#x02019;s Criteria</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;500</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02264;5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;140</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes/No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">495.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">513.59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">431.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">466.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>5</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">626.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">540.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">558.71</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>8</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">470.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>9</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">526.62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>10</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">544.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>11</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">539.62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>12</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">484.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>13</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">503.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>14</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">482.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>15</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">463.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>16</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500.59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>17</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">516.59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>18</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">485.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>19</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">518.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>20</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">511.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">133.83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>21</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">529.59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>22</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">484.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>23</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">484.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>24</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">502.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>25</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">562.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>26</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">611.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>27</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">594.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>28</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">577.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>29</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">566.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.98</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.78</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr></tbody></table><table-wrap-foot><fn><p>MW: molecular weight; nHBD: number of hydrogen bond donors; nHBA: number of hydrogen bond acceptors; Log P: logarithm of partition coefficient of the compound between n-octanol and water; nRotB: number of rotatable bonds; TPSA: topological polar surface area; N<sub>Violation</sub>: number of violated criteria.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-17-01582-t003"><object-id pub-id-type="pii">pharmaceuticals-17-01582-t003_Table 3</object-id><label>Table 3</label><caption><p>IC<sub>50</sub> values of most active spiro-fused [3-azabicyclo[3.1.0]hexane]oxindoles against the <bold>K562</bold>, <bold>HeLa</bold>, <bold>Jurkat</bold>, <bold>CT26</bold> and <bold>PBMC</bold> cell lines for 24 and 72 h.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Compound</th><th colspan="20" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">IC<sub>50</sub>, &#x003bc;M</th></tr><tr><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">K562</th><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">HeLa</th><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Jurkat</th><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">MCF-7</th><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Sk-mel-2</th><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">CT26</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">PBMC</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SI</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SI</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SI</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SI</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SI</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SI</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 h</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">121 &#x000b1; 8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84 &#x000b1; 8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">174 &#x000b1; 17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92 &#x000b1; 9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>8</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83 &#x000b1; 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47 &#x000b1; 5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>11</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33 &#x000b1; 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>17</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35 &#x000b1; 5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">127 &#x000b1; 16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">112 &#x000b1; 9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>18</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 &#x000b1; 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 &#x000b1; 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>22</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39 &#x000b1; 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132 &#x000b1; 16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64 &#x000b1; 6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>23</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">177 &#x000b1; 20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">165 &#x000b1; 16</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>24</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 &#x000b1; 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">113 &#x000b1; 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92 &#x000b1; 11</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 &#x000b1; 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#x000b1; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 &#x000b1; 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 &#x000b1; 1</td></tr></tbody></table><table-wrap-foot><fn><p>*&#x02014;not determined; SI&#x02014;selectivity index, calculated at 72 h.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-17-01582-t004"><object-id pub-id-type="pii">pharmaceuticals-17-01582-t004_Table 4</object-id><label>Table 4</label><caption><p>The effect of cycloadducts <bold>2</bold>, <bold>4</bold>, <bold>8</bold>, <bold>17</bold>, <bold>18</bold> at concentrations of 5, 10 and 20 &#x003bc;g/mL on the distribution of <bold>K562</bold> cells in the cell cycle.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SubG1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">G0/G1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">S</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">G2/M</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SubG1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">G0/G1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">S</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">G2/M</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Control</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.5 &#x000b1; 0.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.5 &#x000b1; 1.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.9 &#x000b1; 1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.1 &#x000b1; 1.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>8 (5 mg/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.1 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63.1 &#x000b1; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.7 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.2 &#x000b1; 0.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Doxorubicin (1 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.0 &#x000b1; 1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.6 &#x000b1; 0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.8 &#x000b1; 1.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.2 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>8 (10 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.1 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73.5 &#x000b1; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.6 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.9 &#x000b1; 0.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Doxorubicin (5 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.1 &#x000b1; 0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.9 &#x000b1; 0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>8 (20 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.6 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72.4 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.0 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1 &#x000b1; 0.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>2 (5 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.3 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47.7 &#x000b1; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.5 &#x000b1; 0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.4 &#x000b1; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>17 (5 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.6 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.1 &#x000b1; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.7 &#x000b1; 1.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>2 (10 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.7 &#x000b1; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.8 &#x000b1; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.6 &#x000b1; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.8 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>17 (10 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.3 &#x000b1; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.5 &#x000b1; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.3 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.8 &#x000b1; 0.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>2 (20 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.8 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72.5 &#x000b1; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.5 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.3 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>17 (20 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74.5 &#x000b1; 0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.4 &#x000b1; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.2 &#x000b1; 0.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>4 (5 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.3 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.6 &#x000b1; 0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.6 &#x000b1; 0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.5 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>18 (5 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.2 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.0 &#x000b1; 0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.4 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.4 &#x000b1; 0.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>4 (10 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.8 &#x000b1; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.9 &#x000b1; 0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.4 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.9 &#x000b1; 0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>18 (10 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.9 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70.1 &#x000b1; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.0 &#x000b1; 0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.0 &#x000b1; 0.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>4 (20 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.9 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.2 &#x000b1; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.4 &#x000b1; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.9 &#x000b1; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>18 (20 &#x003bc;g/mL)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.6 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.0 &#x000b1; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.8 &#x000b1; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.6 &#x000b1; 0.3</td></tr></tbody></table></table-wrap></floats-group></article>